Skip Navigation LinksHome > March/April 2014 - Volume 3 - Issue 2 > Management of Choroidal Neovascularization Secondary to Path...
Asia-Pacific Journal of Ophthalmology:
doi: 10.1097/APO.0000000000000017
Review Article

Management of Choroidal Neovascularization Secondary to Pathological Myopia: The Era of Changes

Ho, Mary MRCS*; Liu, David T.L. FRCOphth, FRCS*†; Young, Alvin L. MMedSc (Hons), FRCS (Irel)*†; Lam, Dennis S.C. MD, FRCOphth*†

Collapse Box

Abstract

Choroidal neovascularization (CNV) secondary to pathological myopia is an important cause of significant visual impairment in young adults. High myopia is particularly prevalent in Asian population. New scientific contributions have been made to the understanding of high myopia and myopic CNV. Treatment for myopic CNV has previously relied on photodynamic therapy, laser photocoagulation, and submacular surgery. The treatment outcomes from these modalities are, however, controversial. The introduction of antiangiogenic agents including bevacizumab and ranibizumab has brought the treatment of myopic CNV into a new era. The purpose of this review was to provide an overview of the natural history of myopic CNV, the prognostic factors, and the various treatment options including laser photocoagulation and photodynamic therapy, with particular attention on antiangiogenic agents.

Copyright © 2014 by Asia Pacific Academy of Ophthalmology

You currently do not have access to this article.

You may need to:

Note: If your society membership provides for full-access to this article, you may need to login on your society’s web site first.

Login

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.